A low-cost, widely available steroid lowered mortality among critically ill COVID-19 patients by one-third in a rigorous large-scale UK trial, Esther Gillmor reports.
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here:
Cookie Policy